前列腺癌的免疫治疗研究进展  

Updated studies on the immunotherapy of prostate cancer

作　　者：刘瑾 李文平(综述)[1] 杨士杰(审校)[1] LIU Jin;LI Wen-ping;YANG Shi-jie(Department of Urology,The Third Hospital of Hebei Medical University,Shijiazhuang,Hebei 050051,China)

机构地区：[1]河北医科大学第三医院泌尿外科,河北石家庄050051

出　　处：《中华男科学杂志》2022年第4期349-355,共7页National Journal of Andrology

摘　　要：前列腺癌是老年男性常见的泌尿生殖系统恶性肿瘤,目前的治疗方法有手术、放疗、化疗和雄激素剥夺治疗,但复发转移患者最终会产生耐药性。近期研究表明前列腺癌是免疫敏感肿瘤,免疫治疗是前列腺癌可行的一种治疗方法,包括疫苗接种、免疫检查点抑制剂、肿瘤微环境调节剂、双特异性抗体、过继细胞转移等。但免疫治疗的不良反应和单药作用有限,限制了其应用,个体化治疗选择和联合用药是研究发展方向。Prostate cancer(PCa)is a common urogenital malignancy in elderly men,for which current treatment strategies include surgery,radiotherapy,chemotherapy and androgen-deprivation therapy.However,PCa patients with recurrence or metastasis may ultimately develop therapeutic resistance.Recent studies show that PCa is an immunosensitive tumor and immunotherapy is a feasible option for its treatment,which involves therapeutic vaccination,immune checkpoint inhibitors,tumor microenvironment regulators,bi-specific antibodies,and adoptive cell metastasis.The application of immunotherapy,however,has been hindered by the adverse reactions of the patients and limited effects of single-drug medication.Individualized treatment and combination therapy are expected to be the alternatives in the development of the treatments of PCa.

关 键 词：前列腺癌 免疫治疗 疫苗接种 免疫检查点抑制剂 肿瘤微环境调节 

分 类 号：R737.25[医药卫生—肿瘤]